44th week of 2012 patent applcation highlights part 48 |
Patent application number | Title | Published |
20120277131 | SLIDING MEMBER - Disclosed is a sliding member having an overlay layer ( | 2012-11-01 |
20120277132 | LUBRICANT COMPOSITION AND BEARING USING SAME - A lubricant composition capable of effectively preventing a rolling surface of a bearing from flaking owing to hydrogen embrittlement. The bearing is lubricated with the lubricant composition. The lubricant composition is lubricating oil or grease. The lubricant composition contains a molybdate. The lubricant composition also contains an organic acid salt. At least one molybdate is selected from sodium molybdate, potassium molybdate, and lithium molybdate. The organic acid salt is a sodium salt of an organic acid having one to 20 carbon atoms. 0.01 to 5 wt % of the molybdate is added to the entirety of the lubricant composition. 5 wt % to 70 wt % of the organic acid salt is added to the addition amount of the molybdate. The lubricant composition forms a film containing a molybdenum compound in addition to an iron oxide film on a worn surface of the bearing. | 2012-11-01 |
20120277133 | FUNCTIONALIZED POLYMERS - This invention relates to functionalized polymers derived from functionalized monomers. The functionalized polymer may be reacted with an enophilic reagent (e.g., maleic anhydride) to form an enophilic reagent modified functionalized polymer. The functionalized polymer may be further reacted with one or more additional reagents, e.g., an oxygen-containing reagent (e.g., alcohol, polyol), a nitrogen-containing reagent (e.g., amine, polyamine, aminoalcohol), a metal, a metal compound, or a mixture of two or more thereof. The invention relates to lubricants, functional fluids, fuels, dispersants, detergents and polymer compositions. | 2012-11-01 |
20120277134 | LUBRICATING OIL COMPOSITION - A lubricating oil composition contains: at least one lubricating base oil selected from the group consisting of a mineral lubricating base oil and a synthetic lubricating base oil; (a) a neutral phosphorus compound; (b) at least one acid phosphorus compound selected from the group consisting of a specific acid phosphate amine salt and a specific acid phosphite; and (c) a sulfur compound. | 2012-11-01 |
20120277135 | LUBRICATING OIL - A lubricating oil composition includes an antibacterial composition, a corrosion preventive, petroleum naphtha, optionally a solvent, and the balance being an oil. The lubricating oil composition may also include acetone. A process for lubricating an object includes the steps of: providing a lubricating oil composition comprising an antibacterial composition, a corrosion preventive, petroleum naphtha, optionally a solvent, optionally acetone, and the balance being an oil; and applying the lubricating oil composition to a surface of the object. | 2012-11-01 |
20120277136 | GREASE COMPOSITION FOR BEARINGS WITH IMPROVED HEAT-RESISTANT ACOUSTIC LIFE - The invention provides a grease composition having (A) a lithium soap thickener, (B) as a base oil an ester type synthetic oil obtainable from an esterification reaction of trimethylolpropane with a fatty acid, and (C) (c-1) a 1-naphthylamine type antioxidant and (c-2) a diphenylamine type antioxidant, wherein the contents of (c-1) and (c-2) are 1.0 to 10 mass% in total, based on the total mass of the composition, and the ratio by mass of (c-1) to (c-2) is in the range from 30:70 to 70:30. | 2012-11-01 |
20120277137 | SKIN CLEANSING AGENT - Provided is a skin cleanser, including the following components (A) to (D): (A) 1 to 30% by weight of a higher fatty acid or a salt thereof; (B) 0.5 to 10% by weight of a polyoxyethylene alkyl ether carboxylic acid or a salt thereof; (C) 0.1 to 10% by weight of an amphiphilic substance having an IOB of 0.25 to 1.2; and (D) 1 to 25% by weight of a water-insoluble particle having an average particle diameter of 50 to 500 μm, in which a weight ratio between the components (A) and (B) “(A)/(B)” is 1/2 to 10/1. | 2012-11-01 |
20120277138 | Consumer Product Packets With Enhanced Performance - The present invention includes a consumer product packet comprising a capsule and a fill composition within the capsule. The capsule has a tack temperature of about 110° F. or higher and substantially dissolves in water within a predetermined time period at a temperature of about 70° F. or lower. In one example, the capsule comprises a film having at least one polymer, at least one plasticizer, and at least one temperature adjusting agent. Dependent on the fill composition, the consumer product packet may be used for any household or personal use. In one example, the fill composition is a detergent concentrate comprises one or more surfactants, one or more humectants, and a coalescing solvent which has hydrophilic-lipophilic balance (HLB) value from about 7 to about 9, wherein the ratio of the one or more humectants to the coalescing solvent is more than 1. | 2012-11-01 |
20120277139 | NOVEL WHITENING AGENTS FOR CELLULOSIC SUBTRATES - This invention relates to novel whitening agents for cellulosic substrates. The whitening agents are comprised of at least two components: at least one chromophore component and at least one polymeric component. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to ultraviolet light, or they may absorb light to reflect these same shades. The whitening agents are further characterized by having a dispersion component value of the Hansen Solubility Parameter of less than or equal to about 17 MPa | 2012-11-01 |
20120277140 | Surfactant Systems For Surface Cleaning - The present invention relates to aqueous surfactant systems that in diluted or undiluted form may be used for cleaning surfaces or may be used as an active cleaning base in various ready-to-use (or in-use) aqueous cleaning compositions suitable for surface cleaning. The invention also relates to a cleaning system comprising a surfactant system of the invention. According to the invention the cleaning efficacy of the surfactant system or cleaning system is increased by reducing or minimizing the size of the surfactants typically used in surfactant systems and reducing or minimizing the water solubility of the surfactant system. | 2012-11-01 |
20120277141 | CALCIUM SEQUESTERING COMPOSITION - This invention relates to compositions which are capable of sequestering calcium ions and are derived in part from renewable carbohydrate feedstocks. The calcium sequestering compositions are mixtures containing one or more hydroxycarboxylic acid salts, one or more oxoacid anion salts, and one or more citric acid salts. | 2012-11-01 |
20120277142 | MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME - Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases. | 2012-11-01 |
20120277143 | IL4/IL13 Binding Repeat Proteins and Uses - IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions. | 2012-11-01 |
20120277144 | NOVEL COMPOUNDS FOR MODULATING NEOVASCULARISATION AND METHODS OF TREATMENT USING THESE COMPOUNDS - The invention relates to a method for modulating neovascularisation of a tissue in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound or a combination of compounds selected from an isolated nucleic acid molecule comprising a gene selected from the group consisting of RIKEN c DNA S9430020K01, Agtrl1, Apelin, Stabilin 1, Stabilin 2, TNFaip8l1, TNFaip8 and FGD5, and homologues thereof; a gene product encoded by said genes, or encoded by homologues of these genes, and functional fragments thereof; an antibody or derivative thereof directed against a gene product of said genes, or encoded by homologues of these genes, and functional fragments thereof, said derivative preferably being selected from the group consisting of scFv fragments, Fab fragments, chimeric antibodies, bifunctional antibodies, intrabodies, and other antibody-derived molecules; an antisense molecule, in particular an antisense RNA or antisense oligodeoxynucleotide, an RNAi molecule (siRNA or mi RNA) or a ribozyme capable of binding under stringent hybridization conditions to a gene or an m RNA gene product of said genes and homologues thereof; a small molecule interfering with the biological activity of a gene product of said genes and homologues thereof, and a (glycol)protein, a hormone and other biologically active compounds capable of interacting with said genes and homologues thereof or with a gene product thereof. | 2012-11-01 |
20120277145 | Compounds - The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example | 2012-11-01 |
20120277146 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 2012-11-01 |
20120277147 | PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS - A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro | 2012-11-01 |
20120277148 | INSULIN ANALOGUES WITH CHLORINATED AMINO ACIDS - An insulin analogue comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The chlorinated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration. | 2012-11-01 |
20120277149 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim | 2012-11-01 |
20120277150 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | 2012-11-01 |
20120277151 | GLP-1 PHARMACEUTICAL COMPOSITIONS - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues. | 2012-11-01 |
20120277152 | COMPRESSED HIGH DENSITY FIBROUS POLYMERS SUITABLE FOR IMPLANT - An embodiment of the present invention may be made by the following steps: providing a mixture comprising a plurality of fibers, a lubricant, and a suspension fluid, with the suspension fluid filling a void space between said fibers and subjecting said mixture to at least one compressive force. The compressive force causes the migration and alignment of said fibers; and may remove substantially all of the suspension fluid from said mixture. The mixture may further comprise a biologically active agent, or a reinforcing agent. | 2012-11-01 |
20120277153 | TREATING LIVER DISEASES - This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided. | 2012-11-01 |
20120277154 | HOMODIMER OF INSULINOTROPIC PEPTIDE ANALOGUES AND METHOD FOR PREPARATION THEREOF AND USE THEREOF - Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs. | 2012-11-01 |
20120277155 | THERAPY FOR KIDNEY DISEASE AND/OR HEART FAILURE - Medical systems and methods for treating kidney disease alone, heart failure alone, chronic kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a natriuretic peptide such as Vessel Dilator to a subject. Methods for increasing and maintaining peptide levels at a certain concentration include direct peptide delivery via either an external or implantable programmable pump. | 2012-11-01 |
20120277156 | INHIBITION OF PATHOLOGICAL BONE FORMATION - Described are methods of inhibiting heterotopic ossification (HO) in a subject in need thereof. The methods involve administering an effective amount of a proprioception inhibitor to the subject, whereby HO is inhibited or prevented. The present invention also relates to a method of treating a subject with bone trauma. This involves administering a proprioception inhibitor to the subject under conditions effective to treat the bone trauma, where the proprioception inhibitor prevents or inhibits HO. | 2012-11-01 |
20120277157 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS - Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease. | 2012-11-01 |
20120277158 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS - The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder. | 2012-11-01 |
20120277159 | METHODS FOR TREATING DEPRESSION USING NCAM PEPTIDE MIMETICS - The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness. | 2012-11-01 |
20120277160 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - Provided are a composition for improving the brain function, which can be orally taken at a low dose, and a method therefor. The composition for improving the brain function contains, as the active ingredient, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Ile or Asn-Ile; and Y is nil or represents Val-Met), X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is abscent or represents Thr-Gln-Thr-Pro, Pro-Leu-Thr-Gln-Thr-Pro, Leu-Thr-Gln-Thr-Pro or Pro; and Y is abscent or represents Val-Met), or a salt of the same. The method for improving the brain function comprises administering said peptide or a salt of the same. | 2012-11-01 |
20120277161 | INHIBITION OF MULTIPLE CELL ACTIVATION PATHWAYS - There is provided a method for inhibiting growth and/or proliferation of a cancer cell. The method comprises treating a cancer cell with an effective amount of a polypeptide providing a cytoplasmic binding domain of a β integrin subunit for binding of ERK2 to inhibit at least one protein kinase, other than a MAP kinase, in a cell activation pathway of the cancer cell. The protein kinases inhibited by the polypeptide may be selected from the group consisting of c-Raf, MEK 1 and kinases in the Src, PI3K, PKB/AKT and PKC families. Methods for the prophylaxis and treatment of cancer are also provided. | 2012-11-01 |
20120277162 | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2012-11-01 |
20120277163 | MicroRNA-10 Antagonists and MicroRNA-10 Targets for Use in the Treatment of a Glioma - The present invention embraces microRNA-antagonists and activators of homeobox D10 protein; Zinc finger, MYND domain containing 11 protein; or RB1-inducible coiled-coil 1 protein for use in decreasing glial tumor cell proliferation and treating glioma. | 2012-11-01 |
20120277164 | GADD45BETA TARGETING AGENTS - Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders. | 2012-11-01 |
20120277165 | METHODS OF MODULATING FUCOSYLATION OF GLYCOPROTEINS - The present invention provides methods and materials useful for monitoring and regulating the glycosylation of glycoproteins that are recombinantly produced from cells. In particular, methods are provided for monitoring and regulating levels of cellular indicators which affect the level of fucosylation produced by cells. | 2012-11-01 |
20120277166 | CONOTOXIN PEPTIDES USEFUL AS INHIBITORS OF NEURONAL AMINE TRANSPORTERS - The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them. | 2012-11-01 |
20120277167 | ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE - Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy. | 2012-11-01 |
20120277168 | KOKUMI-IMPARTING AGENT - A substance capable of imparting a kokumi having CaSR agonist activity is described. This substance is able to impart kokumi in a superior manner, in particular, at the initial taste, and is also highly stable and can easily be produced at a low cost. The present invention thus provides a kokumi-imparting composition which includes such a substance as well as a complex kokumi-imparting composition which includes the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting composition including γ-Glu-Nva (L-γ-glutamyl-L-norvaline), and a complex kokumi-imparting composition including the foregoing substance and another substance having a CaSR agonist activity, in combination. | 2012-11-01 |
20120277169 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES - Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis. | 2012-11-01 |
20120277170 | NUTRITIVE COMPOSITIONS AND METHODS OF USING SAME - The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from strict fluid management. | 2012-11-01 |
20120277171 | Warmi.RTM., natural alternative for the treatment of menopause - Warmi®, composed of glucosinolates, β-sitosterol and citrus flavonoids (hesperidin), is as effective as HRT in reducing menopausal symptoms, Warmi® promotes a healthy cardiovascular system, supports hormonal balance and emotional well-being, improving the quality of life of women during perimenopause and menopause. All of these and the lack of side effects make Warmi® an ideal natural alternative to conventional HRT. | 2012-11-01 |
20120277172 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION - The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided. | 2012-11-01 |
20120277173 | STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc. | 2012-11-01 |
20120277174 | NEW MACROLIDES AND THEIR USE - The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer. | 2012-11-01 |
20120277175 | PHARMACEUTICAL COMBINATIONS, PHARMACEUTICAL COMPOSITIONS, MEDICAMENT AND METHOD FOR THE TREATMENT OF ANIMALS - This invention relates to antihelminthic pharmaceutical combinations comprising iodinated aromatic compounds, such as disophenol or nitroxynil, with other pharmaceutical active ingredients targeting the treatment of animals. More specifically, this invention concerns pharmaceutical compositions comprising disophenol or nitroxynil with at least one other pharmaceutical antihelminthic active ingredient, selected from among benzimidazoles, thiabendazole, levamisole or tetramisole salts, avermectins or milbemycins and, even more preferably, levamisole salts selected from between levamisole chloride or phosphate. | 2012-11-01 |
20120277176 | Protein Arginine Deiminase Inhibitors as Novel Therapeutics for Rheumatoid Arthritis and Cancer - In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm. | 2012-11-01 |
20120277177 | CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-BETA-RIBOFURANOSYL-1H-BENZIMIDAZOLE - The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy. | 2012-11-01 |
20120277178 | COMPOSITIONS AND METHODS FOR TREATING FRAGILE X PREMUTATION RVGG REPEATS-MEDIATED TOXICITY - Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds. | 2012-11-01 |
20120277179 | Edible Energy Composition - The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested. | 2012-11-01 |
20120277180 | Cofactors and Methods for Use for Individuals - Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan based on the genetic variant. Also provided herein are formulations of cofactors determined by the genetic make-up of the individual and methods of determining and producing these formulations. | 2012-11-01 |
20120277181 | LACTULOSE FOR BOWEL EVACUATION - A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed. | 2012-11-01 |
20120277182 | ANOECTOCHILUS SPP. POLYSACCHARIDE EXTRACTS FOR STIMULATING GROWTH OF ADVANTAGEOUS BACTERIA, STIMULATING RELEASE OF GRANULOCYTE COLONY-STIMULATING FACTOR, MODULATING T HELPER CELL TYPE I, AND/OR MODULATING T HELPER CELL TYPE II AND USES OF THE SAME | 2012-11-01 |
20120277183 | PHOSPHATE-BINDING CHITOSAN AND USES THEREOF - The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan. | 2012-11-01 |
20120277184 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES - The invention provides methods for treating, delaying, and preventing pathological conditions caused by pore-forming toxins such as anthrax toxin, α-hemolysin toxin, and ε-toxin using a class of low molecular weight compounds that block the pore formed by these toxins. Specific compounds useful for treating, preventing, or delaying a disease condition caused by | 2012-11-01 |
20120277185 | Pesticidal Carboxamides - To provide novel carboxamides which exhibit an excellent pesticidal activity as pesticides. Carboxamides represented by the following Formula (I) and use thereof as pesticides and an animal parasite control agent: | 2012-11-01 |
20120277186 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions - This application relates to tricyclic compounds of Formula I: | 2012-11-01 |
20120277187 | Agent for Preventing Infection - An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a fat globule membrane component as an active ingredient. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a sphigosine-containing phospholipid and/or a derivative thereof, particularly sphingomyelin, as an active ingredient. | 2012-11-01 |
20120277188 | WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION - The present invention provides a benzoazepine compound represented by following general formula (1): | 2012-11-01 |
20120277189 | WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION - The present invention provides a benzoazepine compound represented by following general formula (1): | 2012-11-01 |
20120277190 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR - Compounds of formula (I) | 2012-11-01 |
20120277191 | FORMS OF CIDOFOVIR - Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs. | 2012-11-01 |
20120277192 | AMINOPYRIMIDINES AS SYK INHIBITORS - The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis. | 2012-11-01 |
20120277193 | Synergistic Combination Therapy - Combinations of compounds are provided that produce a synergistic effect when administered. | 2012-11-01 |
20120277194 | AMINOPROPANOL DERIVATIVES - Compounds of formula I: | 2012-11-01 |
20120277195 | PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients. | 2012-11-01 |
20120277196 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 2012-11-01 |
20120277197 | TIGECYCLINE FORMULATIONS - The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. | 2012-11-01 |
20120277198 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS - The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α.4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof. | 2012-11-01 |
20120277199 | Modulation of Gel Temperature of Poloxamer-Containing Formulations - Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s). | 2012-11-01 |
20120277201 | Use of hydroxyprogesterone derivatives for enhancing health and physical performance - A method for the use of derivatives of hydroxyprogesterone (17-alpha-hydroxypregn-4-ene-3,20-dione) to enhance health and physical performance in humans and more particularly to the use of hydroxyprogesterone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function. | 2012-11-01 |
20120277202 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHODS OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder. | 2012-11-01 |
20120277203 | ANDROSTENEDIOL AS AN INDICATOR FOR ASSESSING ESTROGENICITY - The present invention provides methods of determining whether a female patient will benefit from hormone replacement therapy. | 2012-11-01 |
20120277204 | PYRIDAZINONE COMPOUNDS - The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I | 2012-11-01 |
20120277205 | DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS - The present invention relates to compounds corresponding to formula (I): | 2012-11-01 |
20120277206 | REVERSE TRANSCRIPTASE INHIBITORS - Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders. | 2012-11-01 |
20120277207 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS - The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds. | 2012-11-01 |
20120277208 | BENZAMIDE COMPOUND - [Problem]A compound which is useful as a GK activator is provided. | 2012-11-01 |
20120277209 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS - Pyrazine compounds of formula (I): | 2012-11-01 |
20120277210 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT - A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2012-11-01 |
20120277211 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE - Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status. | 2012-11-01 |
20120277212 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors - The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4. | 2012-11-01 |
20120277213 | ETHYNYL COMPOUNDS - The present invention relates to ethynyl derivatives of formula I | 2012-11-01 |
20120277214 | TRICYCLOPYRAZOLE DERIVATIVES - Compounds which are tricyclopyrazole derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them. | 2012-11-01 |
20120277215 | Organic Compounds - The present invention provides a compound of formula I: | 2012-11-01 |
20120277216 | 1,2-DIHYDRO-2-OXOQUINOLINE COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS - The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. | 2012-11-01 |
20120277217 | Imidazole Derivatives as IDO Inhibitors - Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease. | 2012-11-01 |
20120277218 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME - The compounds and pharmaceutical compositions of the present invention are believed to significantly inhibit Dyrk 1a activity which suggests that the agents could provide therapeutic benefit for Down syndrome, since Dyrk 1a overproduction in Down syndrome appears to account for the developmental cognitive impairment and reduction in neurogenesis. The compounds and pharmaceutical compositions, administered during early post-natal development, may increase neurogenesis and thereby reduce cognitive impairment which may ultimately allow individuals with Down syndrome to live a more independent life. | 2012-11-01 |
20120277219 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations. | 2012-11-01 |
20120277220 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES - The present invention relates to 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, to their preparation and to their therapeutic use. | 2012-11-01 |
20120277221 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 2012-11-01 |
20120277222 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 2012-11-01 |
20120277223 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME - The present invention relates to compounds of formula (I): | 2012-11-01 |
20120277224 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2012-11-01 |
20120277225 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2012-11-01 |
20120277226 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (IA) and (IB): | 2012-11-01 |
20120277227 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (IA), (IB) and (IC): | 2012-11-01 |
20120277228 | Novel Azaheterocyclic Compounds - The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2012-11-01 |
20120277229 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE - In one aspect, the invention relates to substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the PDK1 kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the PDK1 kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2012-11-01 |
20120277230 | COMPOUNDS USEFUL FOR TREATING CANCER - The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a CN group, a hydroxyl group, a COOR | 2012-11-01 |
20120277231 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 2012-11-01 |